Showing 1682 results
-
Press release /Pivotal overall survival data for investigational compound PKC412 (midostaurin) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia Presentations highlight new CTL019 data in…
-
Press release /Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase…
-
Press release /Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx…
-
Press release /New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and…
-
Press release /New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
-
Press release /New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
-
Ad hoc release /Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…